Ahmad Mohammad Mahmoud Altatari

Ahmad Mohammad Mahmoud Altatari

Auto-generated profile, based on publicly available information

Ahmad Mohammad Mahmoud Altatari

Faculty of Medicine, Alexandria University, Alexandria, Egypt

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2026 in Annals of Middle Eastern Medicine
Verified
Journal Article
Closed access
AAAya Abdulrahman Ajeel
Aya Abdulrahman Ajeel
AAAbdullah I. Alzimam
Abdullah I. Alzimam
SASharifah Alraythi
Sharifah Alraythi
AAAhmad Mohammad Mahmoud Altatari
Ahmad Mohammad Mahmoud Altatari
ABAbdullah Bousamri
Abdullah Bousamri
MAMansuor A. Alanazi
Mansuor A. Alanazi
Introduction: Chronic kidney disease (CKD) attributable to high fasting plasma glucose (HFPG) is rising globally, particularly in regions with rapidly increasing dysglycemia such as the Middle East and North Africa (MENA). We assessed long-term trends in HFPG-attributable CKD burden across 21 MENA countries from 1990 to 2023. Methods: Using estimates from the Global Burden of Disease (GBD) 2023 study, we quantified deaths and disability-adjusted life years (DALYs) attributable to HFPG-related CKD at regional, national, age-group, and sex-specific levels. We derived age-standardized mortality rates (ASMRs) and age-standardized DALY rates (ASDRs) and evaluated temporal changes using joinpoint regression to identify significant shifts in burden across the study period. Results: The absolute burden of HFPG-attributable CKD increased substantially across the region, with large rises in both deaths and DALYs. In contrast, ASMRs and ASDRs showed only modest changes, suggesting that population growth and ageing were major contributors to the rising burden. Older adults experienced the highest mortality and DALY rates, and men consistently exhibited greater burden at working ages. National patterns were heterogeneous, with some countries showing declining age-standardized rates while others demonstrated sustained increases. Joinpoint analysis revealed a transition from relative stability in the early 1990s to sustained increases after the late 2000s, with the most rapid acceleration occurring after 2019. Conclusion: HFPG-attributable CKD is an escalating health challenge in the MENA region, driven by rising dysglycemia and demographic change, with substantial variation across countries. Strengthening early detection of dysglycemia and CKD, improving long-term glycemic and blood-pressure control, and expanding access to kidney-protective therapies are critical to mitigating the growing burden.